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In this paper the authors report the evolution of a new automatic
HPLC analyserfor screening haemoglobinopathies. HbA 2 and F
determinations are accurate and reproducible. The analysis time is
short (6"5 min) and there is a good separation between the HbA 2
values of -thalassemia carriersfrom normals and o-thalassemia
carriers, with no overlap between these groups. In addition, the
system is also able to detect and quantitate most of the haemoglobin
variants, particularly those (HbS, HbC, HbE and Hb Lepore)
able to interact with -thalassemia and could make haemoglobin
electrophoresis unnecessary in all samples. The ease of operation
and the limited technical work make this system especially suitable
for laboratories with a high workload and allow the cost ofscreening
to be reduced.
Introduction
Quantitative haemoglobin HbA2 determination is a
critical test for identifying carriers of fl-thalassemia,
because the increase of this minor haemoglobin fraction
is the most relevant diagnostic characteristic of hetero-
zygous fl-thalassemia. Several laboratory techniques
have been developed to measure accurately the HbA2
levels [1-7], but they are all time-consuming manual
methods and measure HbA2 only--a complete haemato-
logical evaluation requires other tests: for example
electrophoresis on different substrates, alkali denaturation
for HbF, and elution or chromatography for quantitation
of haemoglobin variants.
The introduction of a fully automated HPLC system for
qualitative and quantitative haemoglobin analysis has
produced a substantial improvement in the authors’
laboratory [8]. The system performed separation and
quantitative determination of haemoglobin types from
whole blood. Although the method is accurate and
reproducible, there were several problems to be over-
come. These problems included difficult calibration of
the instrument, the need for manual modification and
installation of the program and the long analysis time
(16 min/sample). Recently, a new version of this system
was introduced and the results have improved con-
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siderably. This paper reports on the use of this system in
a screening program for thalassemia.
Materials and methods
The study involved 823 Sardinian adults who were
examined as part of a screening program for thalassemia,
in addition there were 13 subjects who were known
to be carriers of haemoglobin variants. Red blood cell
indices were determined with the Coulter Counter Max
M. (Coulter Electronic) and haemoglobin analysis and
quantitation were performed by HPLC VARIANT (Bio-
Rad Laboratories, Milan, Italy). The VARIANT is a fully
automated HPLC apparatus with a temperature controlled
cation-exchange analytical cartridge (30 x 4"6 mm) and
an increasing ionic strength elution buffer for a differen-
tial separation of haemoglobin components. A dual
wavelength filter photometer (415 and 690 nm) reads the
haemoglobins eluted from the cartridge. For the analysis,
5 gl of EDTA whole blood is automatically diluted with
ml of a haemolysing reagent. Haemolysed specimens
are loaded into a 100-place sampler compartment
maintained at 12 ___
2C. Twenty microlitres of each
sample are sequentially injected at 6-5 min intervals.
Built-in software controls the analysis cycle (elution
gradient, column regeneration) and performs peak
integration. The calibration factors for HbA2 and F
are automatically calculated using a calibrator at the
beginning of each run. The control program for the
instrument is upgraded with an interface card.
Haemoglobin electrophoresis was performed on cellulose
acetate in TrisEDTA borate buffer at pH 8"4, when a
haemoglobin variant was detected citrate agar at pH 6"0
was used.
Globin chain synthesis was carried out on peripheral blood
reticulocytes [9]. The e-globin genotype was defined by
methods based on polymerase chain reaction (PCR),
according to Dod et al. [10] and Bowden et al. [1 1]. The
haemoglobin variants were identified at DNA level by
direct sequencing offl and 6 globin genes after amplification
by PeR [12, 13].
Diagnostic criteria
Subjects with reduced MCV and MCH and increased
(> 3"5) Hba2 were classified as fl-thalassemia carriers,
while subjects with reduced MCV and MCH, normal
serum iron and normal HbA2 and F were classified as
-thalassemia carriers. The diagnosis of the 0-thalassemia
trait was confirmed in a large majority of cases by globin
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Table 1. Analytical imprecision for HbA 2 and HbF.
HbA2, % HbF, %
Within run N Mean___SD CV N Mean 4-SD CV
Table 2. HbA 2 and F in normal subjects and in thalassemia
carriers (mean 4- SD
N A2% F%
Normal 566
Low 15 1"96 + 0"05 2"5 /-trait 163
Normal 15 2"95 + 0"04 1"7 e-trait 94
High 15 4"91 4- 0-05 2"0 15 7"11 4- 0"08 1"2
1"7
Between run N
Low 10 2"09 + 0"03 1"4
Normal 10 3"10 + 0"04 1"4
High 10 7"00 4-0"11 1"6 10 6"95-1-0"12
synthesis (0/fl ratio < 0"9 in 33 subjects) or 0 globin gene
analysis (identification of deletion or non deletion defects,
in 42 subjects).
Results
In a previous paper [8], the authors reported the high
reproducibility and accuracy of HbA2 and F deter-
mination comparing the Diamat HPLC analyser with the
DE-52 microchromatography for HbA2 and with the
alkali denaturation for HbF. The coefficient of variation
within-run was 2"6 for HbA2 and 5"1 for HbF; the
correlation was for HbA2: r= 0"9639 and for HbF:
r 0"9990.
The accuracy of HbA2 (237 samples) and HbF (44
samples) measurements by the Variant analyser was
established by taking the Diamat-HPLC analyser as
reference method--see figure 1. Figure uses the standard
mode of reporting this type of data (the results of method
No. versus the results of method No. 2, top part of the
figure), as well as the method proposed by Bland and
Altman (bottom) I-14]. The mean differences between the
two analysers were -0"01 (HbA2; 95 confidence
2"5 + 0"2 0"6 + 0"4
5"5 + 0"5 1.3 + 1"4
2"4 _+ 0"2 0"5 4- 0"4
intervals +0"31/-0"33%) and -0"22% (HbF; 95%
confidence intervals + 0"64/- 1"08). In conclusion, there
was good agreement between the two methods, both for
HbA2 and HbF.
The analytical imprecision was tested for HbA2 by
running several samples from subjects with low, normal
and high HbA2 levels, and separately from a sample with
increased HbF. The results, reported in table 1, show that
the HbAz and HbF determination is highly reproducible,
with the coefficient of variation never greater than 3.
Table 2 summarizes the values of HbA2 and F found in
a large group of normal subjects, // and 0-thalassemia
carriers. The cut-off limit for HbA2 can be set at 3"5,
with all subjects with values higher than 3"5 being
identified as/-thalassemia carriers.
In this study subjects with different haemoglobin variants
of the (Hb J Sardegna), fl (S, C, G San Jos, E, G
Copenhagen, D, Shelby, Hope, Olbia) and 6 (A2 B, A2
Sant’Antioco, Babinga, A2 Fitzroy) _chains were also
examined. The nucleotide substitution of these variants
have been defined by globin geneDNA sequencing. Figure
2 shows some chromatograms of these variants and figure
3 shows a diagrammatic representation of the relative
positions of some common haemoglobin variants in the
chromatogram. While HbS (figure 2 (a)) and C are eluted
separately after HbAz, Hb Lepore (figure 2(b)) and HbE
are co-eluted with HbA2. In these cases the percentage
of the peak in the HbA2 position will be greater than
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Figure 1. Comparison between Diamat and Variant determinations ofHbA2 (left) and HbF (right), both expressed in percentages.
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Figure 2. Chromatograms from subjects with haemoglobin
variants: (a) HbS; (b) Hb Lepore; (c) HbJ Sardegna and (d)
HbA 2 S. Antioco.
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Figure 3. Diagrammatic representation of the relative chromato-
graphic position of some haemoglobin variants.
10%. In HbS carriers there is a false increase of HbA2
levels in the range 4-0-4"7%. HbJ Sardegna (e His -
Asp)
(figure 2[c]) shows an elution time similar to HbF.
Electrophoresis on cellulose acetate will clear up the
difference between these two haemoglobins, in fact HbJ
Sardegna is an electrophoretically fast-moving variant.
Figure 2(d) shows a double peak near the HbA2 position
due to the presence ofan HbA2 variant (HbA2 S.Antioco
6 93 Lys Gly) and of the normal HbA2 [15]. With the
Variant system, patients homozygous for fl39 mutation
do not show any peak correspondent to the HbA0 elution
time, as expected (not shown). However, with the Diamat
a small peak in the HbA0 position was found in /
homozygotes which is either an artefact or an unidentified
component [8]. All the chromatograms are clear and
easily understandable.
Discussion
The accurate determination of HbA2 and F, and the
detection of the haemoglobin variants, usually require
time-consuming methods. The Variant HPLC system
provides a rapid, simple and reliable separation and
determination of the relative percentage of different
haemoglobin types, particularly haemoglobin A2 and F,
in whole blood. The method is accurate and reproducible.
Other advantages are minimal sample preparation (5 gl
of whole blood diluted automatically 1:200 in a single
step), a short analysis time (6"5 min per sample), and the
ability of the autosampler to analyse up to 100 samples
sequentially and automatically. There is a good separation
ofthe HbA2 values among/-thalassemia carriers, normals
and o-thalassemia carriers, with practically no overlap
between these three groups.
With regards to the detection limits, because of the lack
of pure HbA0, HbA2 and HbF, it was not possible to
perform any specific test so the limits claimed by the
manufacturer, which were set at 0"7, both for HbA2
and HbF, were used.
The system is also able to detect and quantitate most of
the haemoglobin variants and could make haemoglobin
electrophoresis, commonly used in haemoglobinopathies
screening, no longer necessary in all samples. However,
for the identification of any particular haemoglobin
variant, other methods (like sickling test for HbS,
electrophoresis on different substrates, globin chain
analysis, instability tests, protein analysis or DNA
sequence analysis) are required.
There are some limitations in the procedure. Since Hb
Lepore and HbE are co-eluted with HbA2, their presence
in the sample will give a percentage of HbA2 which is
greater than 10. This amount of HbA2 is almost never
present in fl-thalassemia carriers. Therefore samples found
to have a level of HbA2 greater than 10 should be
further tested for the possible presence of a haemoglobin
variant interference. The false increase of HbA2 levels in
HbS carriers is due to the co-elution ofminor components
with HbA2 (possible post-translational modifications of
HbS). This may also occur with haemoglobin variants
eluting after HbA2. HbH (/?4) and gart’s (74) can be
detected in the chromatogram but not quantitated,
because they are eluted prior to the start of integration.
The ease ofoperation and the limited technical work make
this system especially suitable for laboratories with a high
workload; it will also reduce the screening costs for
fl-thalassemia and haemoglobinopathies.
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